What happens after weight-loss injections stop? Two major withdrawal studies found substantial average weight regain. Their results support planning for maintenance before treatment ends, but they do not predict exactly what will happen to one person.
Evidence reviewed September 11, 2026. This article explains selected studies and offers questions for a clinical appointment; it is not a stopping, tapering, or restarting schedule.
For ingredient names, country-specific approvals and safety warnings, start with our Mounjaro vs. Wegovy guide. Tirzepatide is sold under Mounjaro and Zepbound branding depending on market and indication; the study below concerns the ingredient.
Semaglutide: what the STEP 1 extension found
The 2022 extension followed a subset of adults without diabetes after 68 weeks of weekly semaglutide 2.4 mg or placebo. Both study medication and the structured lifestyle intervention ended at week 68. The extension analysis included 327 participants across both groups.
Over the following year, the former semaglutide group regained about two-thirds of its previous weight loss, on average. Its average weight remained approximately 5.6% below the original baseline. Several cardiometabolic improvements moved back toward baseline.
This was an exploratory follow-up of a subset, not a new randomized comparison of stopping versus continuing semaglutide. Because lifestyle support also ended, the result does not isolate medication withdrawal while holding that support constant. These findings concern the studied weekly injection regimen. Read the STEP 1 extension paper.
Tirzepatide: what SURMOUNT-4 found
In SURMOUNT-4, adults with obesity or overweight and a weight-related complication, without diabetes, first received tirzepatide for 36 weeks. The 670 participants subsequently randomized had lost an average of 20.9% of their starting weight.
Over the next 52 weeks, those switched to placebo gained an average of 14.0% relative to their week-36 weight. Those continuing tirzepatide lost a further 5.5%. Lifestyle counseling continued in both groups.
The randomized withdrawal phase supports a maintenance benefit from continuing treatment in this selected population, who had reached a tolerated 10 or 15 mg dose. It does not establish an outcome for every person starting treatment. Eli Lilly funded the trial. Read the SURMOUNT-4 trial.
Two percentages that answer different questions
| Measure | Plain-language example |
|---|---|
| Fraction of weight previously lost | If someone lost 15 kg, regaining two-thirds means gaining 10 kg. |
| Percentage of current body weight | If someone weighs 80 kg, a 14% increase means gaining 11.2 kg. |
Illustrative arithmetic only. These examples are not trial participants or personal forecasts.
The two studies used different designs and cannot show which medicine causes more rebound after stopping. A group average also does not mean that everyone regained all the weight.
Make a maintenance plan with your prescriber
NIDDK explains that treatment duration depends on benefit and side effects; some people may be advised to continue long term. Healthy eating and physical activity remain part of care and may help limit regain after stopping. They cannot promise a particular result. Read NIDDK’s weight-management medication guidance.
Use these questions to make your next appointment concrete:
- Purpose: Which health goals are we treating, beyond a target weight?
- Review: What benefits, side effects and costs should determine whether this treatment continues?
- Follow-up: If treatment changes, when should we meet again, and which changes should prompt an earlier call?
- Support: What eating and activity plan fits my health, daily routine and abilities? Would dietitian support help?
- Access: If cost or supply interrupts treatment, whom should I contact before my medication runs out?
Bring your medication list and a short record of concerns. Ask your prescriber for instructions specific to your product if you need to stop or restart; do not create a dose-spacing or switching plan from these trial averages.
Common questions
Does reaching my goal mean treatment is finished?
It is a useful time for a treatment review. Ongoing benefit, tolerability, health conditions and preferences should inform the next decision with your clinician.
Do these studies prove tapering prevents regain?
No. Neither of the studies summarized here tested a tapering strategy designed to prevent regain. They cannot establish an effective taper or justify a do-it-yourself schedule.
Where can I read about food choices?
Our protein foods vs. powders guide explains serving sizes and labels. It is general food information, not a replacement for an individual maintenance plan.
If side effects are prompting you to consider stopping, read our common side effects and warning signs guide and contact your prescriber for advice.